AllPennyStocks.com Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform

The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.

Other Penny Stock Movers

This Small Cap Is Done Talking About Its Buyback and Ready to Start Buying
This Junior Miner Just Found Gold Hiding Beside a Decades-Old Pit
Utah Copper Explorer Jumps 19% on Surface Assays
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top